Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

OBJECTIVE: The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy e...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Benjamin, Cree, Bruce A. C., Kappos, Ludwig, Montalban, Xavier, Papeix, Caroline, Wolinsky, Jerry S., Buffels, Regine, Fiore, Damian, Garren, Hideki, Han, Jian, Hauser, Stephen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469695/
https://www.ncbi.nlm.nih.gov/pubmed/30820738
http://dx.doi.org/10.1007/s00415-019-09248-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469695/
https://www.ncbi.nlm.nih.gov/pubmed/30820738
http://dx.doi.org/10.1007/s00415-019-09248-6

Ejemplares similares